Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Readmission Risk Factors and Heart Failure With Preserved Ejection Fraction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04008914
Recruitment Status : Completed
First Posted : July 4, 2019
Last Update Posted : July 8, 2019
Sponsor:
Information provided by (Responsible Party):
Dustin Harmon, Ascension Macomb-Oakland Hospital

Brief Summary:
Retrospective review of 492 patient from a small community hospital who did not qualify for participation in the Connect HF study sponsored by DCRI.

Condition or disease Intervention/treatment
Heart Failure Preserved Ejection Fraction Other: retrospective observation

Detailed Description:
Retrospective review of adults above the age of 18 with a primary diagnosis of HFpEF between August 2017 and March 2018. Subjects had to fall into one of two classifications (NYHA Class II-IV or ACC/AHA Stage B-D) and had a life expectancy greater than 6 months are included. Individuals with a terminal illness other than HF, prior heart transplant or on a transplant list, or current/ planned left ventricular assist device excluded. The primary objective of this study is to identify risk factors for readmission in patients discharged with a diagnosis of HFpEF.

Layout table for study information
Study Type : Observational
Actual Enrollment : 492 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Readmission Risk Factors and Heart Failure With Preserved Ejection Fraction
Actual Study Start Date : August 1, 2017
Actual Primary Completion Date : March 1, 2018
Actual Study Completion Date : January 18, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Group/Cohort Intervention/treatment
readmission at 30 days Other: retrospective observation
Retrospective review of study patients excluded from the CONNECT- HF trial who were discharged with a diagnosis of HFpEF between August 1, 2017 and March 1, 2018. Readmission rate at 30 and 90 days along with patient demographics and associated comorbidities were analyzed.

readmission at 90 days Other: retrospective observation
Retrospective review of study patients excluded from the CONNECT- HF trial who were discharged with a diagnosis of HFpEF between August 1, 2017 and March 1, 2018. Readmission rate at 30 and 90 days along with patient demographics and associated comorbidities were analyzed.




Primary Outcome Measures :
  1. Readmission Risk Factors and Heart Failure with Preserved Ejection Fraction [ Time Frame: August 1, 2017 though March 1, 2018 ]
    Retrospective review to identify risk factors for readmission in patients discharged with a diagnosis of HFpEF.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All
Criteria

Inclusion Criteria:

  • History of Heart failure diagnosis admitted for treatment
  • Ejection fraction < 40% by echocardiogram

Exclusion Criteria:

  • Ejection fraction >40% by echocardiogram
  • Chronic Kidney disease requiring dialysis
  • Terminal illness
  • New onset diagnosis of Heart Failure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04008914


Locations
Layout table for location information
United States, Michigan
Ascension Macomb-Oakland Hospital
Warren, Michigan, United States, 48093
Sponsors and Collaborators
Ascension Macomb-Oakland Hospital
Investigators
Layout table for investigator information
Principal Investigator: Dustin Harmon, DO Ascension Macomb-Oakland Hospital

Layout table for additonal information
Responsible Party: Dustin Harmon, Principle Investigator, Ascension Macomb-Oakland Hospital
ClinicalTrials.gov Identifier: NCT04008914     History of Changes
Other Study ID Numbers: AscensionMacombOaklandH
First Posted: July 4, 2019    Key Record Dates
Last Update Posted: July 8, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Dustin Harmon, Ascension Macomb-Oakland Hospital:
Heart Failure
Readmission Risks
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases